vs
Side-by-side financial comparison of LANDSTAR SYSTEM INC (LSTR) and Insulet Corporation (PODD). Click either name above to swap in a different company.
LANDSTAR SYSTEM INC is the larger business by last-quarter revenue ($1.2B vs $783.7M, roughly 1.5× Insulet Corporation). Insulet Corporation runs the higher net margin — 13.0% vs 3.4%, a 9.6% gap on every dollar of revenue. On growth, Insulet Corporation posted the faster year-over-year revenue change (31.2% vs 1.6%). Over the past eight quarters, Insulet Corporation's revenue compounded faster (33.2% CAGR vs -2.2%).
Landstar System, Inc. is an American transportation services company specializing in logistics and, more specifically, third-party logistics. Landstar utilizes an extensive network of over 8,800 independent owner-operators, referred to internally as business capacity owners (BCOs), over 1,000 independent freight agents, and over 70,000 vetted carriers. Landstar provides services principally throughout the United States and to a lesser extent in Canada and between the U.S. and Canada, Mexico, ...
An insulin pump is a medical device used for the administration of insulin in the treatment of diabetes mellitus, also known as continuous subcutaneous insulin therapy . The device configuration may vary depending on design. A traditional pump includes:the pump a disposable reservoir for insulin a disposable infusion set, including a cannula for subcutaneous insertion and a tubing system to connect the insulin reservoir to the cannula.
LSTR vs PODD — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.2B | $783.7M |
| Net Profit | $39.4M | $101.6M |
| Gross Margin | 9.6% | 72.6% |
| Operating Margin | 4.5% | 18.7% |
| Net Margin | 3.4% | 13.0% |
| Revenue YoY | 1.6% | 31.2% |
| Net Profit YoY | 32.3% | 0.9% |
| EPS (diluted) | $1.16 | $1.42 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.2B | $783.7M | ||
| Q3 25 | $1.2B | $706.3M | ||
| Q2 25 | $1.2B | $649.1M | ||
| Q1 25 | $1.2B | $569.0M | ||
| Q4 24 | $1.2B | $597.5M | ||
| Q3 24 | $1.2B | $543.9M | ||
| Q2 24 | $1.2B | $488.5M |
| Q1 26 | $39.4M | — | ||
| Q4 25 | $23.9M | $101.6M | ||
| Q3 25 | $19.4M | $87.6M | ||
| Q2 25 | $41.9M | $22.5M | ||
| Q1 25 | $29.8M | $35.4M | ||
| Q4 24 | $46.2M | $100.7M | ||
| Q3 24 | $50.0M | $77.5M | ||
| Q2 24 | $52.6M | $188.6M |
| Q1 26 | 9.6% | — | ||
| Q4 25 | — | 72.6% | ||
| Q3 25 | — | 72.2% | ||
| Q2 25 | — | 69.7% | ||
| Q1 25 | — | 71.9% | ||
| Q4 24 | — | 72.1% | ||
| Q3 24 | — | 69.3% | ||
| Q2 24 | — | 67.7% |
| Q1 26 | 4.5% | — | ||
| Q4 25 | 2.5% | 18.7% | ||
| Q3 25 | 2.2% | 16.7% | ||
| Q2 25 | 4.6% | 18.7% | ||
| Q1 25 | 3.4% | 15.6% | ||
| Q4 24 | 4.8% | 18.3% | ||
| Q3 24 | 5.2% | 16.2% | ||
| Q2 24 | 5.6% | 11.2% |
| Q1 26 | 3.4% | — | ||
| Q4 25 | 2.0% | 13.0% | ||
| Q3 25 | 1.6% | 12.4% | ||
| Q2 25 | 3.5% | 3.5% | ||
| Q1 25 | 2.6% | 6.2% | ||
| Q4 24 | 3.8% | 16.9% | ||
| Q3 24 | 4.1% | 14.2% | ||
| Q2 24 | 4.3% | 38.6% |
| Q1 26 | $1.16 | — | ||
| Q4 25 | $0.70 | $1.42 | ||
| Q3 25 | $0.56 | $1.24 | ||
| Q2 25 | $1.20 | $0.32 | ||
| Q1 25 | $0.85 | $0.50 | ||
| Q4 24 | $1.30 | $1.38 | ||
| Q3 24 | $1.41 | $1.08 | ||
| Q2 24 | $1.48 | $2.59 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $411.0M | — |
| Total DebtLower is stronger | $26.1M | $930.8M |
| Stockholders' EquityBook value | $799.0M | $1.5B |
| Total Assets | $1.6B | $3.2B |
| Debt / EquityLower = less leverage | 0.03× | 0.61× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $411.0M | — | ||
| Q4 25 | $452.2M | — | ||
| Q3 25 | $434.4M | — | ||
| Q2 25 | $426.2M | — | ||
| Q1 25 | $473.4M | — | ||
| Q4 24 | $566.6M | — | ||
| Q3 24 | $531.3M | — | ||
| Q2 24 | $504.0M | — |
| Q1 26 | $26.1M | — | ||
| Q4 25 | $0 | $930.8M | ||
| Q3 25 | $0 | $934.9M | ||
| Q2 25 | $0 | $939.0M | ||
| Q1 25 | $0 | $1.6B | ||
| Q4 24 | $0 | $1.3B | ||
| Q3 24 | $0 | $1.4B | ||
| Q2 24 | $0 | $1.4B |
| Q1 26 | $799.0M | — | ||
| Q4 25 | $795.7M | $1.5B | ||
| Q3 25 | $888.7M | $1.4B | ||
| Q2 25 | $921.8M | $1.5B | ||
| Q1 25 | $930.8M | $1.3B | ||
| Q4 24 | $972.4M | $1.2B | ||
| Q3 24 | $1.0B | $1.1B | ||
| Q2 24 | $1.0B | $998.4M |
| Q1 26 | $1.6B | — | ||
| Q4 25 | $1.6B | $3.2B | ||
| Q3 25 | $1.7B | $3.0B | ||
| Q2 25 | $1.7B | $3.5B | ||
| Q1 25 | $1.7B | $3.5B | ||
| Q4 24 | $1.8B | $3.1B | ||
| Q3 24 | $1.8B | $3.0B | ||
| Q2 24 | $1.8B | $2.9B |
| Q1 26 | 0.03× | — | ||
| Q4 25 | 0.00× | 0.61× | ||
| Q3 25 | 0.00× | 0.68× | ||
| Q2 25 | 0.00× | 0.64× | ||
| Q1 25 | 0.00× | 1.21× | ||
| Q4 24 | 0.00× | 1.07× | ||
| Q3 24 | 0.00× | 1.21× | ||
| Q2 24 | 0.00× | 1.36× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $183.3M |
| Free Cash FlowOCF − Capex | — | $48.2M |
| FCF MarginFCF / Revenue | — | 6.2% |
| Capex IntensityCapex / Revenue | — | 17.2% |
| Cash ConversionOCF / Net Profit | — | 1.80× |
| TTM Free Cash FlowTrailing 4 quarters | — | $377.7M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $72.7M | $183.3M | ||
| Q3 25 | $89.3M | $125.7M | ||
| Q2 25 | $7.1M | $196.5M | ||
| Q1 25 | $55.7M | $63.8M | ||
| Q4 24 | $61.1M | $147.7M | ||
| Q3 24 | $83.1M | $98.5M | ||
| Q2 24 | $48.1M | $96.5M |
| Q1 26 | — | — | ||
| Q4 25 | $70.5M | $48.2M | ||
| Q3 25 | $86.0M | $100.1M | ||
| Q2 25 | $4.7M | $177.9M | ||
| Q1 25 | $53.8M | $51.5M | ||
| Q4 24 | $54.4M | $94.1M | ||
| Q3 24 | $75.6M | $71.8M | ||
| Q2 24 | $40.6M | $74.0M |
| Q1 26 | — | — | ||
| Q4 25 | 6.0% | 6.2% | ||
| Q3 25 | 7.1% | 14.2% | ||
| Q2 25 | 0.4% | 27.4% | ||
| Q1 25 | 4.7% | 9.1% | ||
| Q4 24 | 4.5% | 15.7% | ||
| Q3 24 | 6.2% | 13.2% | ||
| Q2 24 | 3.3% | 15.1% |
| Q1 26 | — | — | ||
| Q4 25 | 0.2% | 17.2% | ||
| Q3 25 | 0.3% | 3.6% | ||
| Q2 25 | 0.2% | 2.9% | ||
| Q1 25 | 0.2% | 2.2% | ||
| Q4 24 | 0.6% | 9.0% | ||
| Q3 24 | 0.6% | 4.9% | ||
| Q2 24 | 0.6% | 4.6% |
| Q1 26 | — | — | ||
| Q4 25 | 3.04× | 1.80× | ||
| Q3 25 | 4.61× | 1.43× | ||
| Q2 25 | 0.17× | 8.73× | ||
| Q1 25 | 1.87× | 1.80× | ||
| Q4 24 | 1.32× | 1.47× | ||
| Q3 24 | 1.66× | 1.27× | ||
| Q2 24 | 0.91× | 0.51× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
LSTR
Segment breakdown not available.
PODD
| U.S.Omnipod | $567.8M | 72% |
| International Omnipod | $214.0M | 27% |
| Drug Delivery | $1.9M | 0% |
